Your browser doesn't support javascript.
loading
The value of AR-V7 in predicting therapeutic efficiency of abiraterone for CRPC patients / 中华泌尿外科杂志
Chinese Journal of Urology ; (12): 200-204, 2020.
Article in Chinese | WPRIM | ID: wpr-869631
ABSTRACT

Objective:

Determine the relationship between AR-V7 expression and treatment efficiency of abiraterone.

Methods:

A prospective cohort study was conducted to detect CTCs AR-V7 in newly diagnosed CRPC patients, aged ≥18 years who were admitted to the urologic department of Peking University cancer hospital from January 2016 to January 2019, with one or more systemic metastases. All the patients intended to be treated with abiraterone. According to the AR-V7 status, patients were divided into 2 groups (AR-V7 positive and negative). PSA decline time, PSA PFS, clinical status PFS, imaging PFS and CSS are analyzed and compared by t-test and Chi-square between 2 groups.

Result:

49 patients were AR-V7 negative and 28 were AR-V7 positive. Compared with AR-V7 positive patients, PSA decline time (72.04±66.92 vs. 190.11±102.44, P=0.000), PSA non-response rate (6.12% vs. 21.4%, P=0.040) are significantly lower in AR-V7 negative patients. PSA PFS(489.17±269.39 vs. 130.56±120, P=0.010), Clinical PFS (551.91±322.05 vs. 261.44±200.85, P=0.018), and Imaging PFS (523.7±223.28 vs. 247.56±202.80, P=0.003) are significantly longer in AR-V7 negative patients.

Conclusion:

Expression status of AR-V7 is related to the response of abiraterone treatment and the prognosis of the patients.
Full text: Available Index: WPRIM (Western Pacific) Type of study: Observational study / Prognostic study Language: Chinese Journal: Chinese Journal of Urology Year: 2020 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Type of study: Observational study / Prognostic study Language: Chinese Journal: Chinese Journal of Urology Year: 2020 Type: Article